Overview

• The European Medicines Agency rejected lecanemab due to risks like brain swelling and bleeding.
• The drug, known as Leqembi, had shown a 27% reduction in cognitive decline in trials.
• Lecanemab is already approved in the US, Japan, South Korea, China, and Israel.
• The UK's MHRA is still reviewing the drug, with a decision expected soon.
• Experts and Alzheimer's organizations have expressed disappointment but remain hopeful for future treatments.